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Purpose: The aim of this study was to elicit utilities for radioactive iodine-refractory 
differentiated thyroid cancer (RR-DTC) and evaluate the impact of treatment response and 
toxicities on quality of life.
Patients and methods: RR-DTC health states were developed based on data from a previous 
qualitative study and iterative review by clinical experts. Following piloting, health states 
underwent valuation by 100 members of the UK public during time trade-off interviews. Mean 
utilities and descriptive distribution statistics were calculated, and a logistic regression analysis 
was conducted.
Results: The demographic characteristics of the study sample were generally reflective of 
the UK population. Clear differentiation in valuation between health states was observed. No 
response/stable disease had an adjusted utility value of 0.87, with a corresponding gain of +0.04 
following a treatment response and a decline of −0.35 for disease progression. Adverse events 
were associated with utility decrements between −0.47 (grade III diarrhea) and −0.05 (grade I/II 
alopecia).
Conclusion: The trade-off interviews derived utility weights show clear differentiation between 
RR-DTC health states in response to treatment. The values reported in this study are suitable 
for cost-effectiveness evaluations for new treatments in RR-DTC.
Keywords: differentiated thyroid cancer, radioactive iodine-refractory, health-related quality 
of life, health utility, vignette
Introduction
Differentiated thyroid cancer (DTC) is the most common form of thyroid cancer and 
accounts for 80% of cases.1 More prevalent in women than men, DTC typically 
presents at a young age in people aged 45–54 years.2,3 DTC is generally a treatable 
disease with a combination of surgery, radioactive iodine therapy, and ongoing thyroid 
suppression/hormone replacement therapy.4 When compared with other malignancies, 
the prognosis for DTC is favorable with long-term (10 years) survival rates of 90%.5,6 
As a result, thyroid cancer is one of the most prevalent malignancies, with 566,708 
people living with the disease in US.3 It is expected to be the fourth leading cancer 
diagnosis by 2030.7 Therefore, understanding its impact on health-related quality of 
life (HRQL) is of particular importance. In addition, thyroid cancer survivors report 
significant health effects and impact on HRQL,8–10 with even “cured” DTC patients 
experiencing significantly impaired HRQL when compared with controls.9,11,12 The 
development of radioactive iodine-refractory DTC (RR-DTC) substantially changes a 
patient’s prognosis and poses a significant therapeutic challenge.13 Treatment options 
are limited and 10-year survival decreases drastically to ~10%.6 Until recently, doxo-
rubicin, which yields low response rates and is associated with a range of toxicities, 
was the only approved systemic therapy.14 Treatment options have expanded with the 
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introduction of tyrosine kinase inhibitors and the approval of 
sorafenib and lenvatinib.15–17 Due to the long life expectancy 
of patients, targeted agents in DTC are likely to be admin-
istered over decades, and patients will be managing their 
treatment and any related side effects for a longer period of 
time. Therefore, it is very important to understand accurately 
the impact of toxicities on HRQL.
The longevity of this treatment highlights the need to 
assess a risk-to-benefit ratio, and HRQL is a key factor in 
treatment decisions.18 The importance of HRQL in RR-DTC 
is further supported by the results of a recent qualitative study, 
which concluded that more advanced DTC treatment phases, 
including RR-DTC, have a greater impact on HRQL than ear-
lier phases.19 The long duration of DTC therapy has important 
implications for the economic evaluation of new treatments. 
These evaluations require a reliable measure of HRQL 
that reflects value (or utility), and utility values for various 
DTC health states have been published.20–23 Reimbursement 
agencies, including the National Institute for Health & Care 
Excellence (NICE), have raised their expectations regarding 
the suitability of methods for collecting HRQL data. NICE 
states a preference for the use of the EQ-5D-3L, a generic 
measure of HRQL completed by patients.24 However, when 
such data are unavailable, other methods such as statistical 
mapping are recommended. Furthermore, the EQ-5D-3L may 
not always be the most appropriate method for measuring and 
valuing health effects.24 An alternative method for capturing 
utilities is the vignette method, where vignette descriptions 
of health states are valued in a time trade-off (TTO) exercise. 
This method is not advocated by NICE but has been utilized 
frequently in oncology due to the difficulties in capturing 
HRQL data. Despite no methodological guidelines, NICE 
state recommendations regarding how such data should 
be collected. The use of qualitative research with patients 
ensures that the data are rooted in patients’ experience while 
enabling valuation by the general public, a more feasible 
method when considering rare diseases with a small patient 
population, during which the priorities of a wider society 
can be reflected. Thus facilitating the elicitation of HRQL, 
that is, utility values, for use in health economic decision 
models informing Health Technology Assessment (HTA). 
In addition, ensuring that the content of the states reflects the 
five dimensions of the EQ-5D-3L and that valuation meth-
ods (face-to-face TTO interviews with the general public) 
mirror EQ-5D-3L valuation helps to avoid limitations of the 
vignette methodology.
The generally favorable prognosis of DTC has led to 
a commonly expressed view by clinicians of it as a “good 
cancer” with survivors being advised to expect a normal 
life.25,26 However, this is not a view shared by all, and quali-
tative research has found that patients view this description 
as dismissive and not reassuring.26 This may also result in 
a failure to validate a patient’s legitimate health concerns 
in the face of a malignant disease, a situation further con-
founded by the lack of published data reporting the precise 
impact of RR-DTC on HRQL, including possible impacts 
of any relevant toxicities and an absence of published utili-
ties for this phase of the disease. Furthermore, results from 
the recent qualitative study suggested that published utility 
values for earlier DTC disease stages are not generalizable 
to RR-DTC health states due to the greater HRQL impact of 
more advanced treatment phases.19 This vignette study was 
conducted to elicit utilities for RR-DTC health states and 
evaluate the utility impact of specific toxicities associated 
with RR-DTC treatment.
Patients and methods
health state development
Health state descriptions (vignettes) were developed based 
on results of the previous qualitative study in DTC, which 
included 14 patients with RR-DTC,19 input and iterative 
review from clinical experts. One-to-one telephone interviews 
were conducted with six health care professionals (physicians 
and nurses) from the UK and US with experience in treating 
patients with RR-DTC. Interviews were conducted by an 
experienced researcher using a semistructured discussion 
guide, informed by the results of the recent qualitative study, 
other published DTC HRQL literature, and treatment safety 
data. The clinical experts were asked to focus on their experi-
ence of “typical” patients and discuss symptoms, treatment-
related toxicities, and any impact on HRQL that they had 
observed in 50% of their patients. Discussion also covered 
rarer cases to help contextualize their descriptions of the more 
typical RR-DTC patient experience. HRQL was discussed in 
terms of the main domains of health status described in two 
commonly used preference measures, the EQ-5D-3L and 
SF-6D.27,28 The Response Evaluation Criteria in Solid Tumors 
guidelines and The Common Toxicity Criteria were used to 
inform discussion of clinical and patient experience of types 
and levels of treatment response and adverse events (AEs).29,30 
A list of health states, some including AEs selected by the 
experts as the most common and relevant to the HRQL of 
patients with RR-DTC, particularly those receiving tyrosine 
kinase inhibitors, was finalized using feedback provided 
by the clinical experts. The states were as follows: stable/
no response, response (partial and complete), progressive 
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disease, stable/no response with grade III diarrhea, stable/
no response with grade III fatigue, stable/no response with 
grade III hand-foot syndrome (HFS), and stable/no response 
with grades I and II alopecia. In order to standardize data col-
lection and allow comparison of HRQL decrement, the AE 
health states were each combined with the stable disease state. 
Additional AEs that were discussed included hypertension, 
which, despite being reported as a relatively common event, 
was not included due to being asymptomatic in the majority 
of patients, and therefore, exerts little effect on HRQL.
Draft descriptions for each of the health states were devel-
oped and aimed to describe the impact on HRQL across the 
main domains of health status described in the EQ-5D-3L and 
SF-6D.27,28 Expert clinical review critiqued the health states for 
clinical accuracy and relevance. Initial review and feedback 
were provided by further telephone interviews with the two 
US physicians. The health state descriptions were revised 
and sent to the remaining four clinical experts for review. 
In cases of disagreement, the level of RR-DTC experience 
was considered, and clinical practice was valued more highly 
than the involvement in clinical trials, thus to ensure the health 
state descriptions reflected the experience of a typical patient 
and not those of a patient enrolled in a clinical trial.
To ensure that the descriptors were clear and would be 
understood during valuation, piloting via cognitive debriefing 
interviews was carried out with five members of the UK 
general public. Pilot participants were first asked to read and 
rank the health states. The interviewer then used a semistruc-
tured interview guide to explore reasons for their rankings, the 
participants’ interpretation and evaluation of the health state 
descriptions, and their understanding of the terms used and 
the differences between the health states. Following cognitive 
debriefing, the health state descriptions were further refined 
to highlight the differences between states by underlining 
key text in each health state that differentiated one state 
from another. To prevent potential misinterpretation, in the 
health state that included description of HFS, the phrase “skin 
reaction” was revised to “skin condition” to avoid confusion 
with an allergic reaction. Also, the example of difficulty 
“walking long distances” was revised to difficulty “standing 
or climbing stairs” to reduce ambiguity around an impact on 
walking ability or mobility and to prevent overlap with text 
used elsewhere in the stable/no response health state descrip-
tion to describe a more general impact on mobility.
health state valuation
Final health states (Supplementary material) underwent 
valuation by participants from the general public during a 
face-to-face interview using a 0–100 visual analogue scale 
(VAS) and a TTO valuation method. During the VAS rating 
exercise, the participants were asked to rate the individual 
health state descriptions. The titles of the health states were 
not stated to avoid influencing the respondents’ judgement. 
The descriptions were presented in a random order and par-
ticipants placed them on a 100 point VAS. Participants were 
free to place the state of “being dead” at any position on the 
VAS scale; however, the full health state was always placed 
at 100. This task familiarized the participants with the health 
states and the process of rating health descriptions.
The TTO method enables health utility values to be 
derived based upon responses to decision scenarios.31 Inter-
viewers used a TTO board to facilitate the participants’ 
evaluation of how many years of full health they would 
be prepared to trade (lose) to avoid living in the presented 
health state. Participants were presented with a series of 
choices, between (A) living in the health state for 10 years 
and (B) living in a state of full health for 10 − “x” years, and 
asked which they preferred, with x varied until the participant 
indicated they were indifferent between the two choices. If 
during the VAS rating, a participant had placed a health state 
below the state of “dead” and confirmed they considered the 
health state to be worse than being dead, in the TTO valu-
ation, the participants were presented with an alternative 
series of choices, between (A) living in the health state for 
a x years followed by 10 – x years in full health or (B) being 
dead. Again, x was varied until the participant indicated they 
were indifferent between the two choices. The amount of 
time in full health traded to avoid living in the health state 
indicates its value or utility, ranging between 0 representing 
dead and 1 representing full health. The valuation method 
for states worse than dead yields negative values that can 
range between −9 and 0. These were divided by 9 to rescale 
to between −1 and 0.
The participants also completed a sociodemographic 
questionnaire, which was used for the purposes of sample 
description and the EQ-5D-3L.
Informed written consent was obtained from each 
pilot and valuation study participant. The study protocol 
conformed to ethical guidelines of the 1975 Declaration of 
Helsinki.
Participants
A total of 100 members of the UK public underwent TTO 
interviews to value the defined health states. These par-
ticipants were members of the general UK population to 
represent UK societal perspectives in line with the published 
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guidance for elicitation of utility values for use in health 
economic decision models informing HTA.24,32 They were 
recruited by five experienced field interviewers in different 
geographical UK locations (Bolton, Dunblane, Leamington 
Spa, Newcastle, and Sheffield).
Eligibility criteria included 18+ years of age, currently 
resident in the UK, able to understand the survey as judged 
by the investigator, and provided informed consent. Partici-
pants with an acute illness or cognitive impairment that may 
interfere with the study requirements were excluded.
Analyses
Mean TTO utilities and descriptive distribution statistics were 
calculated for each health state from the interview data. A 
regression analysis was conducted during which utilities were 
first transformed using a logistic function − −



log ,
1 utility
utility
 
which resulted in an empiric distribution resembling a normal 
distribution. In order to calculate the transformation, negative 
values were set to 0.02, and values of 1.0 were set to 0.98. 
The incremental impact of health states was estimated using 
a multivariable mixed effects model, which estimated the 
impact of health states relative to a base state of stable disease 
with no AEs. The following additional explanatory sample 
variables were included in the full mixed effects model: age, 
sex, employment status, educational qualification status, 
marital status, and self-reported EQ-5D-3L domain scores 
(moderate or extreme problem vs no problem). Adjusted 
predicted utilities were calculated with the sample variables 
found to significantly predict utility set to UK normative 
values. These significant sample variables reported EQ-5D- 
3L usual activity and anxiety/depression domain scores and 
educational qualification status.
Results
Participants
The demographic characteristics were generally reflective of 
the UK population (Table 1).33 Minor discrepancies in the study 
sample included higher proportions of students, those who had 
completed university, and married individuals. The sample 
was predominantly of white ethnicity (92%), which is repre-
sentative of the general UK population; however, there was 
an absence of participants of black ethnicity. EQ-5D-3L data 
suggest that the study sample was healthier and reported fewer 
health-related problems than the general population.34 This is 
likely to reflect that individuals with ongoing health problems 
may be less likely to participate in this type of research study, 
a finding consistent with previous vignette studies.35
Observed utilities for rr-DTc health 
states
Mean utility values derived from the TTO interviews indi-
cate how participants in the study differentiated between 
the RR-DTC health states (Table 2). As demonstrated by 
no overlap in the 95% confidence intervals (CIs), for the 
health states that included a grade III AE (diarrhea, fatigue, 
or HFS), mean utility values were significantly lower than 
for the no response/stable health state. However, the no 
response/stable and the fatigue AE states were separated by 
only 0.0001 (lower 95% CI no response/stable state: 0.7663; 
upper 95% CI fatigue state: 0.7662). The mean utility value 
for no response/stable with grades I and II alopecia was also 
lower than no response/stable, although this difference was 
not statistically significant.
When comparing the results from the VAS exercise 
and TTO interviews, the health state ranking from “best” 
to “worst” shows logical ordering and consistency. All 
health states containing descriptions of an AE were rated as 
worse than the no response/stable health state, with grade III 
diarrhea rated as the lowest state.
During the TTO interviews, spontaneous comments made 
by participants that were relevant to the valuation of the 
health states were documented. These comments suggest that 
the health states were interpreted meaningfully and provide 
further context to the study results. When considering the 
stable/no response state, one participant felt this state was 
“not too bad” and another summarized the state as “Only 
have pain sometimes, not too many awful symptoms”. 
A key feature of the response health state was regarding the 
improvement in the condition, “you are getting better”. The 
severity of progressive disease was recognized, in particular, 
the depressed mood, pain, and distress related to the dete-
rioration in health. Participants commented that they “Don’t 
like pain, low mood and distress” and “it’s getting worse so 
give up, no point continuing”.
With regard to the AEs, alopecia was generally thought to 
not have a large impact on the quality of life due to no effect 
on functioning. Comments like “Can still work” and “Could 
live without my hair” exemplify this opinion. On contemplat-
ing grade III fatigue, some participants thought that fatigue 
is “Just tiredness, can deal with this” and that they “Can live 
with being tired.” HFS provoked mixed responses with some 
imagining the pain to be very difficult to overcome, “Would 
have had enough pain – after 3 years. A miserable life” and 
others feeling that it would not hamper their lives severely, 
“Difficult but life is still there”. Diarrhea was considered to be 
very challenging to cope with, with participants commenting 
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“no social life – no real life” and that they “Couldn’t deal 
with this, family not to see”.
Modeled health state values
Results from the multivariable model regression analysis 
included z-scores, which can be compared against the 
standard normal distribution. In this analysis, all of the 
treatment response and AE health states were shown to be 
statistically significant in predicting transformed utility. The 
majority of other covariates were not statistically significant, 
with the exception of educational qualifications and two 
EQ-5D-3L variables (usual activity and anxiety/depression). 
Table 1 Participant sociodemographics and eQ-5D-3l responses
Participants  
(n=100)
UK census (Office of National 
Statistics, 2011)
sex (male), n 45 49%
Mean age, years (sD) 41.9 (15.9) 38.2
ethnic background
White 92 92.1%
Mixed race 2 1.9%
Asian/Asian British 3 4.0%
chinese 3 not captured
Main activity
employed 65 73%
student 18 5.2%
retired 9 3%
stay at home 6 5.2%
Qualifications
completed university 47 27%
Left school at 18 with qualifications  
or technical/vocation qualification
29 16%
Left school at 16 with qualifications  
or no formal qualification
15 51%
Other 9 6%
relationship status
single 25 36%
Partnership 10 –
Married 59 48%
Divorced/separated 4 10%
Widowed 2 5%
eQ-5D-3l responses Moderate (%) Extreme (%) Moderate (%) Extreme (%)
Mobility 9 0 18.3 0.1
self-care 0 0 4.1 0.1
Usual activities 7 1 14.2 2.1
Pain/discomfort 18 1 29.2 3.8
Anxiety/depression 9 1 19.1 1.8
Abbreviation: sD, standard deviation.
Table 2 Mean observed utilities for rr-DTc health states and incremental impact of health states on utilities compared to a base state 
of stable/no response with no adverse events
Parameter Observed mean utilitya Unadjustedb Adjustedc
Mean utility  
(standard deviation)
95% confidence  
interval
Utility 
value
95% confidence  
interval
Utility 
value
95% confidence  
interval
Base state – stable/no  
response
0.80 (0.19) 0.77, 0.84 0.86 0.83, 0.90 0.87 0.84, 0.91
response to therapy 0.86 (0.15) 0.83, 0.89 +0.04 0.01, 0.07 +0.04 0.01, 0.07
Progressive disease 0.50 (0.28) 0.45, 0.56 −0.37 −0.43, −0.31 −0.35 −0.41, −0.29
Diarrhea 0.42 (0.29) 0.36, 0.48 −0.48 −0.54, −0.43 −0.47 −0.52, −0.41
Fatigue 0.72 (0.24) 0.67, 0.77 −0.08 −0.13, −0.04 −0.08 −0.12, 0.04
hand and foot syndrome 0.52 (0.30) 0.46, 0.58 −0.35 −0.42, −0.29 −0.34 −0.40, 0.28
Alopecia 0.75 (0.21) 0.71, 0.79 −0.05 −0.09, −0.01 −0.05 −0.08, 0.01
Notes: aMean observed TTO health state utilities. bDerived from reduced parameter model (health states only). cAdjusted for educational qualification level and EQ-5D-3L 
(usual activities and anxiety/depression) ratings using UK norms.
Abbreviations: rr-DTc, radioactive iodine-refractory differentiated thyroid cancer; TTO, time trade off.
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Results from the mixed effect model of the health states and 
these significant variables are shown in Table 3.
The incremental impact of health states on utilities was 
then compared to a base state of stable/no response with 
no AEs (Table 2). Two sets of predicted values are listed, 
the first based on the health state only model (unadjusted) 
and the second from an adjusted model (data shown in 
Table 2). To generate predicted values from the adjusted 
model, EQ-5D-3L usual activities and anxiety/depression 
domain and educational qualification variables were set to 
UK normative values. The presence of a response (partial/
complete) was associated with an increase in the utility 
of 0.04 irrespective of adjustment. The largest utility 
decrement was associated with grade III diarrhea, which 
resulted in a −0.48 decrease in utility in the health state only 
model (unadjusted) and −0.47 based in the adjusted model. 
Progressive disease was also associated with a decrease in 
utility of −0.37 in the health state only model and −0.35 in 
the adjusted model.
Observed versus predicted utility values
Observed mean TTO values were compared with the pre-
dictions from the health state only model, and the adjusted 
model, with EQ-5D-3L, and qualification variables set to UK 
normative values (Table 2). The pattern of results across the 
health states was consistent across the three sets of utility 
values.
Discussion
This study aimed to elicit utility values for the HRQL impact 
of RR-DTC across different treatment responses and AE 
health states. The results demonstrated clear differentiation 
in valuation between health states, with response (partial or 
complete) to treatment valued as having the least impact on 
HRQL, and stable/no response plus grade III diarrhea being 
valued as the most burdensome health state. The AE with the 
least associated burden was alopecia (grades I/II), followed 
by fatigue (grade III). These findings were further supported 
by the alignment of findings across the VAS and TTO results 
and the consistency of the values produced during the regres-
sion analysis with the untransformed data.
An important observation is the comparatively large dif-
ference between stable/no response and progressive disease 
states when compared with previous vignette studies in other 
malignancies.35,36 This is likely to be due to relatively high 
utility of the stable/no response health state. This interpreta-
tion is consistent with views expressed by the clinical experts 
consulted during the development of the health states and 
published DTC management guidelines.37 The change from 
stable/no response to disease progression is more substantial 
as a result, representing a transition from a “positive” state 
to a “negative” state. In DTC clinical practice, a transition 
from a progressive disease to a stable disease state repre-
sents an important benefit as a subset of patients, even some 
with quite advanced disease, will live with and die with, not 
Table 3 Parameter estimates of time trade-off utilities (mixed effects model) including statistically significant health states and sample 
variables in the overall multivariable model
Parameter Parameter  
estimate
Standard  
error
P-value 95% confidence  
intervals
intercept 1.548 0.177 0.000 1.2, 1.9
Treatment response health states
stable/no response
response (partial/complete) 0.406 0.139 0.004 0.13, 0.68
Progressive disease −1.845 0.139 0.000 −2.12, −1.57
stable treatment response + Ae health states
Ae: diarrhea −2.325 0.139 0.000 −2.6, −2.05
Ae: fatigue −0.576 0.139 0.000 −0.85, −0.30
Ae: hFs −1.793 0.139 0.000 −2.07, −1.52
Ae: alopecia −0.356 0.139 0.011 −0.63, −0.08
eQ-5D-3l
eQ-5D: any usual activity problems −0.871 0.403 0.031 −1.66, −0.08
eQ-5D: any anxiety/depression problems 1.238 0.465 0.008 0.33, 2.15
Qualifications
Left school at 18 with qualifications  
or technical/vocational qualifications
0.470 0.254 0.064 −0.33, 0.97
Left school at 16 with qualifications  
or no formal qualifications
0.861 0.335 0.010 0.20, 1.52
Abbreviations: Ae, adverse event; hFs, hand and foot syndrome.
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from, their DTC. However, although disease stabilization 
is an important treatment goal in DTC, analyses show that 
patients with responsive disease are likely to experience 
a longer progression-free survival than those with stable 
disease.38 These landmark analyses are not without some 
bias, yet nonetheless, if a lack of progression is considered 
to be a positive situation, a response is at least likely to 
prolong this state.
Another observation is the magnitude of impact of certain 
AEs. Stable/no response plus grade III diarrhea was valued 
as the most burdensome health state with a mean observed 
utility of 0.42. However, the values for the diarrhea health 
state are lower than previous estimates from vignette studies 
conducted in different malignancies. For example, a similar 
vignette study in metastatic renal cell carcinoma reported a 
mean utility of 0.53 for grade III diarrhea.39 Similarly, studies 
in metastatic breast cancer and non-small-cell lung cancer 
observed values of 0.61 and 0.61, respectively.35,36 This 
may reflect differences in the interpretation of AEs and/or 
variation in the health state descriptions used between studies 
or differences in the samples and their views regarding the 
burden of different health states. In addition, two studies 
used standard gamble rather than TTO methods for health 
state valuation,35,36 which is likely to explain some of the 
between-study variations in values elicited.
Also of potential interest is the relatively low valued 
HRQL impact of alopecia (mean observed utility for stable 
disease with alopecia grades I/II of 0.75, compared with 0.80 
for stable disease without). Given thyroid cancer is more 
prevalent in women than in men, it is possible that the impact 
of alopecia as an AE associated with treatment may be valued 
differently by a RR-DTC patient population than the general 
public in which the sexes are more equally represented. An 
exploratory analysis was conducted to examine the impact of 
sex on preferences around alopecia in this study. The findings 
were consistent with the hypothesis that women were more 
concerned with alopecia than men; however, the results were 
not conclusive. While for many regions societal valuation is 
required for health utilities for use in economic evaluation 
of treatments, the potential relevance of alopecia to female 
DTC patients should not be overlooked, as a patient may 
consider alopecia to be of higher significance than observed 
during this study.
Strengths and limitations
The vignette approach has its limitations, and the data derived 
from generic measures such as the EQ-5D-3L are preferred by 
many decisions makers. However, capturing representative 
HRQL data from people with rare forms of advanced cancer 
presents many challenges. The method used in this study to 
estimate utilities is dependent on the robustness of the meth-
odology used to develop the health state vignettes. To address 
this, the vignette development was informed by literature 
review, qualitative work with patients and physicians, and 
additional rounds of interviews with clinical experts and the 
general public.
The extreme rarity of RR-DTC also presents an important 
challenge, as many clinicians lack the treatment experience 
necessary to accurately describe relevant HRQL factors, and 
recruiting for a patient-only study lacks feasibility. However, 
this was overcome by the involvement of clinical experts with 
60 years combined experience in treating RR-DTC, who see 
between two and 30 patients each month. The guidance pro-
vided by these experts facilitated the development of accurate 
and representative disease-related health states, which could 
undergo valuation by members of the general public. This 
valuation by the general public is also beneficial, as it consid-
ers the priorities of a wider society rather than just those held 
by a small subgroup of patients. This methodology also meets 
the requirements for normalization and subsequent health 
economic decision models informing HTA. The vignette con-
tent was also structured around the domains of the EQ-5D- 
3L and SF-6D in order to ensure that the main aspects of 
HRQL were included rather than just those directly affected 
by RR-DTC. Therefore, the approach was used to place the 
problems associated with RR-DTC, its treatments, and the 
side effects in a more general health context, thus facilitating 
comparison with other conditions.
The small sample size in the valuation may be a limitation 
that could affect the representativeness of the results for the 
general UK population. Some evidence from the EQ-5D-3L 
data suggest that the sample were relatively healthier than 
the UK general population.34 When compared to the Office 
of National Statistics census data,33 students/university com-
pleters and married people were overrepresented in the cur-
rent study. However, any effect on the mean utilities elicited 
from this sample was explored in regression analysis, with 
predicted utility values adjusted for significant sample vari-
ables to bring the observed values closer to those expected 
from a more normative UK sample.
The health states developed and valued in this study 
limited the valuation of each AE to the context of stable/no 
response and did not evaluate the impact of AEs when com-
bined with other treatment responses. However, the predic-
tive values offer the potential to estimate the impact of AEs in 
other health state combinations. It is plausible that the burden 
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of AEs might be lower for people who were experiencing a 
response to treatment, and further qualitative work would be 
needed to assess the adaptation required. A useful source for 
the implementation of utilities in cost-effectiveness models is 
the NICE guidance document, which discusses the adjusting 
and combining of health state utility values.32
During analysis, utility point estimates were devised 
using three different methods, mean values calculated directly 
from the observed TTO data, unadjusted values modeled by 
regression analysis, and adjusted values modeled using UK 
normative values for certain sample variables. Although 
the pattern of results was consistent across the analyses, the 
regression analysis generally yielded results that were slightly 
higher than those directly calculated from the observed TTO 
data. As per with mapping to estimate health-related utility, 
the appropriate model type differs depending on the dataset 
and how it is applied. Standard econometric and statistical 
techniques and judgement based on prior knowledge of the 
clinical relationship between variables should be used to 
inform model selection and application. The properties of 
the sample dataset should be used to inform model selection, 
and a justification should be provided explaining why the 
selected regression model was chosen.40
Conclusion
In conclusion, the RR-DTC treatment response and associ-
ated AE health states developed and evaluated during this 
study show clear differentiation. Utility values demonstrated 
that the treatment response (partial or complete) health state 
was valued as having the least negative impact on HRQL, 
and stable/no response plus grade III diarrhea was valued 
as the most burdensome health state. The order and magni-
tude of HRQL impact reflected by these utility values were 
consistent with clinical opinion. The values reported in this 
study are suitable for use in cost-effectiveness evaluations 
for new treatments in RR-DTC.
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Supplementary materials
Final health states with descriptions
stable/no response
The differences in health state descriptions were highlighted 
by underlining key text in each health state that differentiated 
one state from another.
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many 
years.
•	 Your illness is not getting better with treatment, but it is 
not currently getting any worse.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You sometimes feel tired and lack energy.
•	 You are able to walk around as normal and you are able 
to wash and dress yourself.
•	 You are able to perform usual activities such as working 
but you may need to rest, which can limit your social 
activities.
•	 You sometimes experience pain.
•	 You are relieved that your illness is currently not getting 
any worse, but you are uncertain how long this will last 
and you are worried about the future.
•	 Your mood can often feel low, which causes strain on 
your closest relationships.
response
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many years.
•	 Your illness is currently showing some signs that it is 
responding to treatment, so getting better.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You sometimes feel tired and lack energy.
•	 You are able to walk around as normal and you are able 
to wash and dress yourself.
•	 You are able to perform usual activities such as working 
but you may need to rest, which can limit your social 
activities.
•	 You sometimes experience pain.
•	 You are relieved and happy your illness is getting better 
but are uncertain how long this will last, which causes 
you some worry about the future.
•	 Your mood can sometimes feel low, which can cause 
strain on your closest relationships.
Progressive disease
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many 
years.
•	 Your illness is getting worse despite treatment.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You are often tired and lack energy.
•	 You have some problems walking and you sometimes 
find it hard to wash and dress yourself.
•	 You are not able to perform some of your usual activi-
ties such as working full time and you often need to rest, 
which limits your social activities.
•	 You often experience pain.
•	 You are very distressed that current treatment is not work-
ing and your illness is getting worse. You feel fearful 
about the future.
•	 You often have low mood and may have feelings of 
depression. This causes significant strain on your closest 
relationships.
stable + grade 3 diarrhea
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many 
years.
•	 Your illness is not getting better with treatment, but it is 
not currently getting any worse.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You experience 7 episodes of diarrhea a day. You expe-
rience diarrhea during the night, which can interrupt your 
sleep. You can occasionally lose control over your bowel 
movements.
•	 You feel tired and lack energy.
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•	 You are able to walk around as normal, but because of 
your diarrhea you do not want to be far from a toilet. You 
are able to wash and dress yourself.
•	 You are not able to perform some of your usual activities 
such as working full time because you need to rest and 
you have to plan your day to be close to a toilet. You may 
prefer to stay at home or close to home. This has a large 
impact upon your social activities.
•	 You experience mild pain, including stomach cramps.
•	 You are relieved that your illness is currently not getting 
any worse but you are uncertain how long this will last 
and you are worried about the future.
•	 Your mood can often feel low, which causes strain on 
your closest relationships.
stable + grade 3 fatigue
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many 
years.
•	 Your illness is not getting better with treatment but it is 
not currently getting any worse.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You feel tired and lack energy most of the time.
•	 You are able to walk but only for short distances. You are 
able to wash and dress yourself.
•	 You are not able to perform some of your usual activi-
ties such as working full time. You need to plan your 
day in order to take regular breaks to rest or sleep more. 
This significantly limits your time and energy for social 
activities.
•	 You sometimes experience pain.
•	 You are relieved that your illness is currently not getting 
any worse but you are uncertain how long this will last 
and you are worried about the future.
•	 Your mood can often feel low, which causes strain on 
your closest relationships.
stable + grade 3 hFs
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many 
years.
•	 Your illness is not getting better with treatment, but it is 
not currently getting any worse.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You experience a skin condition that causes redness, peel-
ing, dryness, blistering, and tenderness on your hands and 
feet.
•	 You sometimes feel tired and lack energy.
•	 You have significant problems with walking and you have 
some problems with washing and dressing yourself.
•	 You are able to perform some of your usual activities but 
have difficulty performing any that involve using your 
hands or feet. For example, you can experience difficulty 
using a keyboard, holding a pen, standing, or climbing 
stairs. This can limit your work and social activities.
•	 You experience pain, especially in your hands and feet.
•	 You are relieved that your illness is currently not getting 
any worse, but you are uncertain how long this will last, 
and you are worried about the future.
•	 Your mood can often feel low, which causes strain on 
your closest relationships.
stable + grades 1 or 2 alopecia
•	 You are currently undergoing a treatment for a long-term 
serious illness, which you have lived with for many years.
•	 Your illness is not getting better with treatment, but it is 
not currently getting any worse.
•	 You sometimes have discomfort in your neck related to 
trouble swallowing or mild swelling in your neck.
•	 You have a dry mouth, which causes you discomfort 
especially on waking, when talking for a long time or 
eating. You need to regularly drink water to relieve this 
sensation and have to carry water with you to do so.
•	 You have lost some or all of your hair.
•	 You sometimes feel tired and lack energy.
•	 You are able to walk around as normal, and you are able 
to wash and dress yourself.
•	 You are able to perform usual activities such as working, 
but you may need to rest, which can limit your social 
activities.
•	 You sometimes experience pain.
•	 You are relieved that your illness is currently not getting 
any worse, but you are uncertain how long this will last 
and you are worried about the future.
•	 Your mood can often feel low, which causes strain on 
your closest relationships.
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1572
Fordham et al
